Mesoblast fuses Phase II
Tuesday, 28 April, 2009
Melbourne’s Mesoblast has received approval to being a Phase II trial of its allogeneic stem cell product NeoFuse in cervical spine fusion.
The trial, to be held at Melbourne’s Epworth Hospital, will compare NeoFuse with autograft. Twenty-four patients with irreversible, end-stage degenerative disc disease will take part in the randomised, controlled trial.
Mesoblast is also working on lumbar spinal fusion and on repair or regeneration of discs in patients with earlier stage disease.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
